Novartis reports updated Phase II DLBCL data for Kymriah

Novartis AG (NYSE:NVS; SIX:NOVN) reported updated data from the pivotal Phase II JULIET trial of Kymriah tisagenlecleucel to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL). The data were released in an abstract ahead of the American Society of Hematology

Read the full 425 word article

User Sign In